Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Roche announces Ambry Genetics as first US CSP for NimbleGen SeqCap EZ Exome workflow

Roche NimbleGen announces that Southern California (Aliso Viejo) based genomic services provider Ambry Genetics has officially become a Certified Service Provider (CSP) for the NimbleGen SeqCap EZ Exome workflow. They will provide target-enrichment services using NimbleGen SeqCap EZ Human Exome coupled with next-generation sequencing services for genetic research.

9 Sep 2010

Anchor Therapeutics collaborates with OMJPI to develop GPCR targeted therapeutic compounds

Anchor Therapeutics today announced that it has entered into a collaboration and license agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. with the goal of developing G protein coupled receptor (GPCR) targeted therapeutic compounds utilizing Anchor's proprietary pepducin technology.

9 Sep 2010

CombinatoRx is now Zalicus

CombinatoRx, Incorporated today announced that it has changed its name to Zalicus Inc. The company will begin trading under the new ticker symbol ZLCS on the NASDAQ Global Market at market open on September 9, 2010.

9 Sep 2010

Multi-disciplinary team awarded grant to develop interdisciplinary oncology palliative care education program

A multi-disciplinary team representing the schools of Medicine, Nursing and Social Work at the University of Louisville, as well as clinical pastoral education programs in three Louisville hospitals, has been awarded a grant of $1,518,092 from the National Institutes of Health that will fund the development, implementation and evaluation of an interdisciplinary oncology palliative care education program. Work related to the project will begin immediately.

9 Sep 2010

US Oncology selects PatientPoint's self-service solutions to enhance patient experience

PatientPoint, a provider of multi-channel self-service applications for the healthcare industry, today announced that US Oncology, the leading integrated oncology company supporting more than 1,300 affiliated physicians in 500 locations throughout 39 states, has selected PatientPoint solutions to provide self-service technologies to enhance the patient experience.

9 Sep 2010

Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase 3 VELOUR clinical trial of aflibercept (VEGF Trap) in patients with metastatic colorectal cancer (mCRC) will continue to completion as planned, with no modifications due to efficacy or safety concerns. This decision is based on the recommendation of an Independent Data Monitoring Committee (IDMC) following a planned interim analysis.

9 Sep 2010

Hormone treatment with chemotherapy results in deadly side-effect in neuroblastoma children

Children given a hormone growth factor alongside chemotherapy for the aggressive cancer neuroblastoma are less likely to suffer a potentially deadly side-effect, according to a major international study published today (Tuesday) in the Journal of Clinical Oncology.

9 Sep 2010

Two genes linked to ovarian clear cell carcinoma

Scientists at the Johns Hopkins Kimmel Cancer Center have identified two genes whose mutations appear to be linked to ovarian clear cell carcinoma, one of the most aggressive forms of ovarian cancer. Clear cell carcinoma is generally resistant to standard therapy.

9 Sep 2010

BC gynecologists initiate campaign to reduce ovarian cancer mortality

Gynecologic oncologists with the Ovarian Cancer Research Program at Vancouver General Hospital (VGH) and the BC Cancer Agency have begun an important campaign that will reduce deaths from ovarian cancer.

9 Sep 2010

Cachexia reduces function and changes muscle structure of heart in mice with colon cancer

The wasting disease associated with some cancers that is typically seen affecting skeletal muscles can also cause significant damage to the heart, new research in mice suggests.

9 Sep 2010

Santarus, VeroScience enter agreement to commercialize CYCLOSET drug for type 2 diabetes

Santarus, Inc., S2 Therapeutics, Inc. and VeroScience LLC today announced that they have entered into a distribution and license agreement granting Santarus exclusive rights to manufacture and commercialize CYCLOSET (bromocriptine mesylate) tablets in the U.S.

9 Sep 2010

$GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL$

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

GlaxoSmithKline and Genmab A/S announced today the start of a Phase III study in patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL) who did not respond to or progressed during, or within 6 months of a rituximab containing regimen.

9 Sep 2010

ARID1A gene links ovarian cancer to endometriosis

Researchers with the Ovarian Cancer Research Program of BC (OvCaRe) reveal a major new cancer gene-ARID1A. Mutations are frequent in this gene and link two types of ovarian cancer to endometriosis.

9 Sep 2010

Halozyme Therapeutics offers to sell 8.3 million shares of common stock

Halozyme Therapeutics, Inc. today announced that it is offering to sell 8.3 million shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering

9 Sep 2010

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.

8 Sep 2010

Positive results from YM BioSciences' CYT997 Phase I study for vascular disruption in tumors

YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.

8 Sep 2010

Champions Biotechnology signs agreement to test Cephalon's CEP-32496 in Biomerk Tumorgraft platform

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, announced the establishment of an agreement with Cephalon, Inc., a global biopharmaceutical company, for the testing of the Cephalon novel B-Raf inhibitor CEP-32496 in Champions' Biomerk Tumorgraft™ platform.

8 Sep 2010

PLX4032 trial shows high degree of selectivity to achieve tumor shrinkage

Plexxikon today announced publication of key data in this week's edition of Nature demonstrating that the high degree of selectivity of PLX4032 (RG7204) enables substantial RAF/MEK/ERK pathway inhibition, which may be necessary to achieve significant tumor shrinkage and clinical response in patients with BRAF mutant melanoma.

8 Sep 2010

TransOral Robotic Surgery removes head and neck cancer tumors, while preserving speech

An incisionless robotic surgical procedure is offering patients a new option to remove certain head and neck cancer tumors without visible scarring, while preserving speech and the ability to eat.

8 Sep 2010

Silence Therapeutics receives two patents for RNA interference therapeutics

Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).

8 Sep 2010

Oncology News and Research

Further Reading

Roche announces Ambry Genetics as first US CSP for NimbleGen SeqCap EZ Exome workflow

Anchor Therapeutics collaborates with OMJPI to develop GPCR targeted therapeutic compounds

CombinatoRx is now Zalicus

Multi-disciplinary team awarded grant to develop interdisciplinary oncology palliative care education program

US Oncology selects PatientPoint's self-service solutions to enhance patient experience

Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

Hormone treatment with chemotherapy results in deadly side-effect in neuroblastoma children

Two genes linked to ovarian clear cell carcinoma

BC gynecologists initiate campaign to reduce ovarian cancer mortality

Cachexia reduces function and changes muscle structure of heart in mice with colon cancer

Santarus, VeroScience enter agreement to commercialize CYCLOSET drug for type 2 diabetes

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

ARID1A gene links ovarian cancer to endometriosis

Halozyme Therapeutics offers to sell 8.3 million shares of common stock

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

Positive results from YM BioSciences' CYT997 Phase I study for vascular disruption in tumors

Champions Biotechnology signs agreement to test Cephalon's CEP-32496 in Biomerk Tumorgraft platform

PLX4032 trial shows high degree of selectivity to achieve tumor shrinkage

TransOral Robotic Surgery removes head and neck cancer tumors, while preserving speech

Silence Therapeutics receives two patents for RNA interference therapeutics

Cancer Research eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News